Lipoprotein Apheresis and Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors in Patients With Heterozygous Familial Hypercholesterolemia: A One Center Study.

Vana KolovouNiki KatsikiStamatis MakrygiannisSophie MavrogieniNikoletta KarampetsouAthanasios ManolisAndreas MelidonisDimitri P MikhailidisGenovefa D Kolovou

Published in: Journal of cardiovascular pharmacology and therapeutics (2020)

PCSK9i can reduce LDL-C more consistently over time compared with a transient decrease following LA in HeFH patients. PCSK9i therapy may reduce the frequency of LA. Larger trials are required to establish the clinical implications of PCSK9i in patients previously on LA.

Keyphrases

end stage renal disease
low density lipoprotein
ejection fraction
newly diagnosed
chronic kidney disease
peritoneal dialysis
stem cells
patient reported outcomes
brain injury
early onset
patient reported
smoking cessation